Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC5513 + QL1706 ± platinum in advanced solid tumors
CTR20254895Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of QLC5513 in Nonhematologic neoplasms (2 arms), sponsored by Qilu Pharmaceutical. Started Dec 2025; status: active.
02
Drugs
QLC5513
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254895.